Ayble Health, an AI-enabled virtual digestive health clinic, has closed an oversubscribed $16 million Series A round led by Neon. The funding brings the Boston-based company's total capital raised to over $27 million. The company plans to expand its services beyond gastrointestinal conditions into autoimmune health. Ayble now covers 80 million Americans through partnerships with payers, employers, and health systems, and is in-network with most commercial health plans. Ayble's multidisciplinary care model combines GI specialists, dietitians, behavioural health experts, and AI technology. The company has published 16 peer-reviewed clinical studies and reports an average 47% improvement in GI symptoms for patients within four weeks. Founder Sam Jactel, who has inflammatory bowel disease, said the funding will deepen AI precision care capabilities whilst extending services to autoimmune conditions.

Flexspace today announced the launch of a corporate solution for hybrid-remote companies providing employees a seamlessly integrated platform to discover, bo...